Estimating the Incidence and Prevalence of IgA Nephropathy in the U.S.
Author Information
Author(s): DeCongelio Marc, Ali Sarah N., Furegato Martina, Bhattacharjee Sandipan, Fernandes Ancilla W.
Primary Institution: Otsuka Pharmaceutical Development and Commercialization, Inc.
Hypothesis
What is the incidence and prevalence of immunoglobulin A nephropathy (IgAN) in the United States?
Conclusion
The study estimated the incidence and prevalence of IgAN in the U.S. population for 2021 to be between 198,887 and 208,184 persons.
Supporting Evidence
- 43 pathologists reported evaluating a mean of 169 kidney biopsies in the past year.
- 8.7% of the biopsies evaluated were confirmed to have IgAN.
- Annual incidence rates were estimated at 2.1 and 2.2 per 100,000.
- Prevalence rates were estimated at 59.9 and 62.7 per 100,000.
Takeaway
Doctors looked at kidney biopsies to find out how many people in the U.S. have a kidney disease called IgA nephropathy, and they found that many people have it.
Methodology
An online survey with pathologists and insurance claims data were used to estimate IgAN frequency nationwide.
Potential Biases
The study may not represent uninsured populations and had missing racial/ethnic data.
Limitations
The study faced limitations such as restricted availability of biopsy results and potential double-counting of patients in claims data.
Participant Demographics
{"age":{"mean":41.1,"median":40},"sex_distribution":{"male":63.0,"female":36.0},"race_distribution":{"White":42.1,"African American/Black":19.3,"Asian":15.6,"Latino/Hispanic":12.4,"Other":0.8,"Unknown":9.8}}
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website